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Background. Faldaprevir is a potent, once-daily hepatitis C virus (HCV) NS3/4A protease inhibitor. Studies
were performed to investigate potential drug interactions between faldaprevir and the commonly used antiretrovirals
darunavir/ritonavir, efavirenz, and tenofovir to guide the coadministration of faldaprevir with these agents in human
immunodeﬁciency virus/HCV–coinfected patients.
Methods. In 3 open-label, phase 1 pharmacokinetic (PK) studies, healthy adult volunteers received (1) daruna-
vir/ritonavir (800 mg/100 mg once daily) with and without faldaprevir (240 mg once daily); (2) faldaprevir (240 mg
twice daily) with and without efavirenz (600 mg once daily); or (3) faldaprevir (240 mg twice daily) or tenofovir (300
mg once daily) alone and in combination. To assess potential drug interactions, geometric mean ratios and 90%
conﬁdence intervals for PK parameters were calculated. Safety was evaluated.
Results. Efavirenz decreased faldaprevir area under the concentration-time curve (AUC) by 35%, Cmax by 28%,
and Cmin by 46%, consistent with induction of CYP3A by efavirenz. Tenofovir decreased faldaprevir AUC by 22%,
which was not considered to be clinically relevant. Faldaprevir had no clinically relevant effects on darunavir or
tenofovir PK (15% and 22% AUC increase, respectively). Adverse events were consistent with the known safety pro-
ﬁles of faldaprevir and the antiretrovirals being examined.
Conclusions. No clinically signiﬁcant interactions were observed between faldaprevir and darunavir/ritonavir or
tenofovir. A potentially clinically relevant decrease in faldaprevir exposure was observed when coadministered with
efavirenz; this decrease can be managed using the higher of the 2 faldaprevir doses tested in phase 3 trials (240 mg
once daily as opposed to 120 mg once daily).
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Faldaprevir (BI 201335) is a selective novel hepatitis C
virus (HCV) NS3/4A protease inhibitor that has shown
potent in vitro inhibition of HCV genotypes 1, 4, 5, and
6 [1]. Unlike the protease inhibitors boceprevir and te-
laprevir, which are administered 2–3 times daily, the
long elimination half-life of faldaprevir (20–30 hours)
allows oral once-daily administration [2]. Faldaprevir,
in combination with pegylated interferon-α (peg-IFN)
and ribavirin (RBV), has been investigated in phase 3
clinical trials in HCV genotype 1–infected patients at
doses of 120 and 240 mg once daily. The STARTVerso1
trial in treatment-naive patients showed that faldaprevir
plus peg-IFN and RBV was effective and well tolerated,
and achieved sustained virologic response rates of 79%
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(120 mg once daily) and 80% (240 mg once daily) at 12 weeks
following treatment, compared with 52% in patients who re-
ceived placebo plus peg-IFN and RBV (P < .0001) [3]. In addi-
tion, the STARTVerso4 trial investigated faldaprevir (120 and
240 mg once daily) in combination with peg-IFN/RBV in 308
treatment-naive or previously relapsed patients coinfected
with human immunodeﬁciency virus (HIV) and HCV [4]. Pre-
liminary data from this trial have demonstrated high sustained
virologic response rates with faldaprevir treatment (HCV RNA
undetectable 4 weeks after completing therapy): 79% and 84%
in patients treated with 240 mg once daily for 12 and 24 weeks,
respectively, and 72% in patients treated with 120 mg once daily
for 24 weeks [4].
HIV coinfection accelerates HCV disease progression and in-
creases the risk of advanced ﬁbrosis, cirrhosis, and hepatocellu-
lar carcinoma [5–8]. As such, coinfected individuals have an
urgency for HCV treatment. Treatment guidelines recommend
that in HIV/HCV-coinfected patients receiving combination
antiretroviral (ARV) therapy (cART), HCV treatment should
be administered where feasible [9–11], and should be initiated
when HIV replication is controlled [11]. Therefore, there is a
great need for effective HCV treatments that have a low poten-
tial for drug–drug interactions with ARVs and can be coadmi-
nistered safely with most or all contemporary cART regimens.
Faldaprevir at steady state after 240 mg twice-daily dosing is a
weak inhibitor of cytochrome P450 (CYP) 2C9 and a moderate
inhibitor of CYP3A [12], and in vitro studies have shown that
faldaprevir is a CYP3A substrate [13].
Here we describe the results from 3 phase 1 pharmacokinetic
(PK) studies with faldaprevir conducted in healthy volunteers.
The primary objective was to investigate the potential drug in-
teractions with darunavir/ritonavir, efavirenz, and tenofovir to
guide the safe coadministration of faldaprevir and these antire-
trovirals in HIV/HCV genotype 1–coinfected patients.
METHODS
Study Drugs
In separate studies, recommended clinical doses of darunavir/
ritonavir (800 mg/100 mg once daily), efavirenz (600 mg once
daily), or tenofovir disoproxil fumarate (300 mg once daily)
were administered to healthy volunteers. Faldaprevir daily
doses were 240 mg once daily in the darunavir/ritonavir study
and 240 mg twice daily in the efavirenz and tenofovir studies.
The faldaprevir 240 mg twice-daily dosing used in the efavirenz
and tenofovir studies in healthy volunteers was chosen to pro-
vide exposure comparable to that observed with faldaprevir
240 mg once daily in HCV-infected patients, which is the high-
est dose being investigated in phase 3 trials [14]. In all studies,
faldaprevir loading doses were used for the ﬁrst dose (see below),
similar to the loading dose schedule used in patients with HCV.
Study Designs
Three open-label phase 1 PK studies were conducted in healthy
adult volunteers (Figure 1). Healthy male and female volunteers
aged 18–55 years with a body mass index of 18.5–29.9 kg/m2
were enrolled. All studies were approved by the responsible insti-
tutional review board and were carried out in compliance with
the Declaration of Helsinki, in accordance with the International
Conference on Harmonisation Harmonised Tripartite Guideline
for Good Clinical Practice and applicable regulatory require-
ments. Each participant provided written informed consent
prior to initiation of study procedures.
Darunavir/Ritonavir Study
To assess the effects of faldaprevir on the PK of darunavir when
coadministered with ritonavir, subjects received faldaprevir on
days 9–16 and darunavir plus ritonavir on days 1–16. Faldaprevir
was given as a loading dose (480 mg) on day 9 followed by 240 mg
once daily thereafter. Ritonavir is a CYP3A inhibitor that increases
exposure of coadministered HIV protease inhibitors metabolized
by CYP3A [15]. In vitro studies have shown that faldaprevir is a
CYP3A substrate [13]. A dose of faldaprevir 240 mg once daily
was selected for this study population because of the expected
increase in faldaprevir exposure in the presence of ritonavir.
Efavirenz Study
To assess the effects of efavirenz (a moderate CYP3A inducer
[16]) on the PK of faldaprevir, subjects received faldaprevir
on days 2–18 and efavirenz 600 mg once daily on days 10–18
(Figure 1). Faldaprevir was given as a loading dose (480 mg ini-
tially then 240 mg 12 hours later) when ﬁrst administered (day
2), followed by 240 mg twice daily thereafter. To assess the effect
of faldaprevir and combined effects of faldaprevir and efavirenz
on CYP3A metabolism, oral midazolam 7.5 mg once daily was
administered as a probe substrate on days 1, 9, and 18.
Tenofovir Study
To assess the effects of faldaprevir on the PK of tenofovir and
vice versa, subjects received faldaprevir on days 8–22 and teno-
fovir 300 mg once daily on days 1–15. Faldaprevir was given as a
loading dose on day 8 (480 mg initially then 240 mg 12 hours
later), followed by 240 mg twice daily until day 21, and 240 mg
administered in the morning only on day 22.
Pharmacokinetic Evaluation
Blood samples were collected at predetermined time points (Fig-
ure 1). Plasma concentrations of drugs of interest were determined
by commercially available liquid chromatography–tandem mass
spectrometry methods (Tandem Laboratories, Salt Lake City,
Utah). The lower limits of quantiﬁcation for the study medica-
tions were faldaprevir 2 ng/mL; darunavir 25 ng/mL; midazolam
and 1-hydroxymidazolam 0.2 ng/mL; and tenofovir 1 ng/mL.
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Samples containing analyte and internal standard were extracted
and analyzed in an API 3000 (darunavir), API 4000 (faldaprevir),
or API 5000 (midazolam/1-hydroxymidazolam and tenofovir)
mass spectrometer (AB SCIEX, Framingham, Massachusetts).
Quantitation was determined using linear (faldaprevir, midazo-
lam/1-hydroxymidazolam, and tenofovir) or quadratic (daruna-
vir) weighted regression analysis (1/x2) of peak area ratios of
analytes and internal standards. Calibration standards were
placed at the beginning and end of each bioanalytical run. The
calibration curves were linear, and ranges were faldaprevir 2–
2000 ng/mL; darunavir 25–12 500 ng/mL; midazolam and 1-hy-
droxymidazolam 0.2–10 ng/mL; and tenofovir 1–500 ng/mL.
Assay performance during the study was assessed by back-calcu-
lation of calibration standards, assessment of the standard curve
ﬁt, and comparison with quality control samples of blank human
plasma. Adequate accuracy and precision of the assay were ob-
served when compared with quality control samples.
Statistical Analysis
Steady-state PK parameters, including area under the plasma
concentration-time curve (AUC), minimum plasma concentra-
tion (Cmin), maximum plasma concentration (Cmax), time to
Cmax (Tmax), and oral clearance (CL/F) were calculated using
noncompartmental PK analysis (Pharsight WinNonlin version
5.3, Mountain View, California). To assess potential drug inter-
actions, adjusted geometric mean ratios (GMRs) and 2-sided
90% conﬁdence intervals (CIs) for AUC, Cmax, and Cmin were
calculated using SAS version 9.2 (Cary, North Carolina).
Safety Evaluation
Safety was assessed by physical examination, monitoring of
vital signs, laboratory tests, 12-lead electrocardiography
(ECG), and adverse events (AEs) at prespeciﬁed time-points
during the study. ECGs were assessed at screening, at end of
study visit, and as medically necessary based on investigator
judgment. AEs were monitored at screening, every day during
treatment, and at the end of study visit. Subjects were also re-
quired to report AEs spontaneously, including time of onset,
duration, and intensity. AE intensity was graded as mild
(awareness of a sign or symptom, which was easily tolerated),
moderate (discomfort enough to cause interference with usual
activity), or severe (incapacitating or causing inability to work
or to perform usual activities). The relationship between study
treatment and AEs was assessed by the investigator.
RESULTS
Subjects
Forty-ﬁve healthy volunteers received study treatment: 14
in the darunavir/ritonavir study, 15 in the efavirenz study,
and 16 in the tenofovir study. Most subjects were male (76%
overall; range, 60%–86% across the 3 studies; Table 1). Baseline
Figure 1. Study designs and pharmacokinetic (PK) sampling schedule for the darunavir/ritonavir (A), efavirenz (B), and tenofovir (C) studies. Shaded boxes
indicate PK sampling days. Abbreviations: b, twice daily; B, faldaprevir loading dose within twice-daily schedule (480 mg followed by 240 mg 12 hours
later); q, once daily/single dose; Q, faldaprevir loading dose within once-daily schedule (480 mg).
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characteristics were similar between study groups except
for race (50% white, 50% black in the tenofovir study,
and 100% white in other studies; Table 1). Four subjects dis-
continued treatment because of AEs (2 in the efavirenz study
and 2 in the tenofovir study). All other subjects completed
the studies.
Pharmacokinetics
Steady-state PK parameters for faldaprevir and coadministered
drugs are shown in Tables 2 and 3, respectively; adjusted GMRs
and 90% CIs for AUC, Cmax, and Cmin are shown in Figure 2A
and 2B.
Darunavir/Ritonavir Study
With faldaprevir at steady state, darunavir AUC increased by
approximately 15%, Cmax increased by 28%, and Cmin decreased
by 12% (Table 3; Figure 2B). These changes were not considered
to be clinically relevant.
Efavirenz Study
Faldaprevir steady-state exposure was lower when coadminis-
tered with efavirenz compared with faldaprevir alone, with an
approximate 35% decrease in AUC, 28% decrease in Cmax,
and 46% decrease in Cmin (Table 2; Figure 2A). Furthermore,
as would be expected following induction of CYP3A by efavir-
enz, faldaprevir CL/F was higher when faldaprevir was coadmi-
nistered with efavirenz (Table 2).
Midazolam AUC after a single dose increased by approxi-
mately 124% when coadministered with faldaprevir alone (con-
sistent with moderate inhibition of CYP3A by faldaprevir), and
decreased by approximately 61% when coadministered with
Table 2. Steady-State Pharmacokinetic Parameters for Faldaprevir, With and Without Coadministered Drug
Parameter
Geometric Mean (Geometric CV%) of Faldaprevir
240 mg QD Faldaprevir + 800 mg QD Darunavir +100 mg
QD Ritonavir (n = 14)
AUCτ,ss, ng × h/mL 115 000 (58.3)
Cmax,ss, ng/mL 8780 (51.4)
Tmax,ss, h 2.6 (35.3)
Cmin,ss, ng/mL 2660 (78.5)
CL/F,ss, mL/min 34.9 (58.3)
240 mg BID Faldaprevira (n = 15) 240 mg BID Faldaprevira + 600 mg QD Efavirenz (n = 14)b
AUC0–12,ss, ng × h/mL 225 000 (91.1) 146 000 (148)
Cmax,ss, ng/mL 24 000 (76.4) 17 200 (111)
Tmax,ss, h
c 3.0 (0.0–4.2) 2.0 (1.0–4.0)
Cmin,ss, ng/mL 14 700 (119) 7650 (277)
c
CL/F,ss, mL/min 17.8 (91.1) 27.5 (148)
240 mg BID Faldaprevir (n = 14) 240 mg BID Faldaprevir + 300 mg QD Tenofovir (n = 16)
AUC0–12,ss, ng × h/mL 523 000 (101) 418 000 (69.3)
Cmax,ss, ng/mL 50 400 (91.3) 41 700 (51.4)
Tmax,ss, h
c 3.5 (1.5–8.0) 4.0 (2.0–8.0)
Cmin,ss, ng/mL 40 000 (113) 31 000 (79.5)
CL/F,ss, mL/min 7.7 (101) 9.6 (69.3)
Abbreviations: AUC, area under the concentration-time curve; AUCτ, area under the concentration–time curve of the analyte in plasma at steady state over a uniform
dosing interval τ; BID, twice daily; CL/F, oral clearance; Cmax, maximum plasma concentration; Cmin, minimum plasma concentration; CV%, percent coefficient of
variation; QD, once daily; ss, steady state; Tmax, time to maximum plasma concentration.
a A single dose of midazolam (7.5 mg) was also coadministered.
b n = 13 for Cmin.
c Median and range.
Table 1. Subject Baseline Characteristics
Characteristic
Darunavir/
Ritonavir Study Efavirenz Study Tenofovir Study
Subjects, No. 14 15 16
Male sex, No.
(%)
12 (85.7) 9 (60.0) 13 (81.3)
Age, y,
median
(range)
42.0 (20–55) 31 (20–53) 37 (25–54)
BMI, kg/m2,
median
(range)
22.9 (19.3–29.3) 22.6 (19.1–30.6) 26.6 (20.2–29.7)
Race, %
White 100 100 50.0
Black . . . . . . 50.0
Abbreviation: BMI, body mass index.
Faldaprevir/ARV Drug Interaction Studies • CID 2014:59 (15 November) • 1423
both faldaprevir and efavirenz, indicating a net induction of
CYP3A activity by the combination (Table 3; Figure 2B). Trends
in AUC for the primary metabolite 1-hydroxymidazolam cor-
responded with inhibition of CYP3A at the earlier phase and
induction of CYP3A at the late phase (data not shown).
Tenofovir Study
Tenofovir had a small effect on steady-state faldaprevir exposure
(approximate 22% decrease in AUC, 18% decrease in Cmax, and
25% decrease in Cmin; Table 2; Figure 2A), which was not consid-
ered clinically relevant. Similarly, faldaprevir effects on the
steady-state PK of tenofovir (approximate 22% increase in
AUC, 5% decrease in Cmax, and 47% increase in Cmin; Table 3;
Figure 2B) were not considered clinically relevant given the rela-
tive safety of tenofovir and are consistent with the PK of tenofovir
when coadministered with other protease inhibitors [17].
Safety
Across all studies, AEs were mild or moderate in intensity
(Table 4), and all AEs resolved within the follow-up period.
AEs were consistent with the known safety proﬁles of faldapre-
vir and the ARVs being examined. In all studies, no severe AEs
were reported and no deaths occurred.
In the darunavir/ritonavir study, treatment-related AEs oc-
curred in 6 subjects (43%) during treatment with darunavir/ri-
tonavir and 11 subjects (79%) during treatment with darunavir/
ritonavir plus faldaprevir. In the efavirenz study, all subjects had
at least 1 treatment-related AE, and in the tenofovir study, treat-
ment-related AEs were reported in 15 subjects (94%) when fal-
daprevir and tenofovir were coadministered and in 9 subjects
(56%) during treatment with faldaprevir alone. Gastrointestinal
and nervous system disorders were the most commonly report-
ed across all studies (Table 4). Rash was reported in 7 subjects
(47%) who received efavirenz and faldaprevir, compared with 1
subject (6%) who received tenofovir and faldaprevir; no subjects
on darunavir/ritonavir and faldaprevir reported skin-related
events. Jaundice was seen in 6 (40%) and 5 subjects (31%) in
the efavirenz and tenofovir studies, respectively. Hepatobiliary
disorders were not observed in subjects who received daruna-
vir/ritonavir and faldaprevir.
Table 3. Pharmacokinetic Parameters for Darunavir, Midazolam, and Tenofovir, With and Without Coadministered Faldaprevir
Parameter
Geometric Mean (Geometric CV%) of Coadministered Drug
800 mg QD Darunavir +
100 mg QD Ritonavir (n = 14)
240 mg QD Faldaprevira +
800 mg QD Darunavir + 100 mg
QD Ritonavir (n = 14)
AUCτ,ss, ng × h/mL 57 200 (29.5) 66 000 (39.9)
Cmax,ss, ng/mL 4930 (23.9) 6330 (26.5)
Tmax,ss, h 1.7 (33.9) 2.1 (37.3)
Cmin,ss, ng/mL 1330 (49.5) 1170 (90.3)
CL/F,ss, L/h 14.0 (29.5) 12.1 (39.9)
Midazolama (n = 15)
240 mg BID Faldaprevir +
Midazolama (n = 15)
240 mg BID Faldaprevir +
Midazolama +
600 mg QD Efavirenz (n = 14)
AUC0–∞, nmol × h/L 278 (28.3) 624 (54.3) 110 (88.1)
Cmax, nmol/L 110 (45.6) 121 (46.1) 44.9 (101)
Tmax, h
b 1.0 (0.5–1.5) 1.0 (0.5–3.0) 0.7 (0.5–3.0)
Cmin, ng/mL 1.4 (49.1) 3.3 (124) 1.3 (53.2)
CL/F, L/h 82.9 (28.3) 37.0 (54.3) 209 (88.1)
300 mg
QD Tenofovir (n = 16)
240 mg BID Faldaprevir +
300 mg QD Tenofovir (n = 16)
AUC0–24,ss, ng × h/mL 2700 (26.5) 3290 (19.6)
Cmax,ss, ng/mL 300 (27.3) 284 (16.6)
Tmax,ss, h
b 2.0 (0.5–4.0) 2.0 (0.5–3.0)
Cmin,ss, ng/mL 54.0 (26.7) 79.4 (21.5)
CL/F,ss, mL/min 1850 (26.5) 1520 (19.6)
Abbreviations: AUC, area under the concentration-time curve; AUCτ, area under the concentration-time curve of the analyte in plasma at steady state over a uniform
dosing interval τ; BID, twice daily; CL/F, oral clearance; Cmax, maximum plasma concentration; Cmin, minimum plasma; CV%, percent coefficient of variation; QD,
once daily; ss, steady state; Tmax, time to maximum plasma concentration.
a Single oral administration of 7.5 mg midazolam.
b Median and range.
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Four subjects discontinued study treatment because of an AE,
including 2 subjects (a male and a female) receiving faldaprevir
alone in the tenofovir study (1 due to mild rash and the other due
to moderate myalgia) and 2 subjects (a male and a female) receiv-
ing efavirenz, faldaprevir, and midazolam (1 due to moderate
rash, and 1 due to moderate rash with mild transient elevation
in alanine aminotransferase and aspartate aminotransferase).
Consistent with the known inhibition by faldaprevir of uridine
diphospho-glucuronosyltransferase 1A1 activity and unconjugat-
ed bilirubin uptake in the liver [18], total bilirubin concentrations
in plasma increased during faldaprevir treatment. Mean total bi-
lirubin concentrations increased between baseline and last treat-
ment from 8.5 to 19.1 µmol/L in the darunavir/ritonavir study,
from 9.7 to 32.9 μmol/L in the efavirenz study, and from 13.6
to 67.8 µmol/L in the tenofovir study. In all studies, bilirubin
increased with increasing concentrations of faldaprevir; however,
these elevations rapidly returned to normal after treatment was
completed and were generally not associated with alanine amino-
transferase, aspartate aminotransferase, or γ-glutamyl transferase
elevations. The observations in bilirubin reported here are consis-
tent with those seen in previous faldaprevir studies [2,3]. As such,
faldaprevir-associated increase in bilirubin is not considered clin-
ically relevant. There were no clinically relevant changes in any
other laboratory parameters or vital signs, and no abnormal
ECG ﬁndings.
DISCUSSION
Treatment guidelines recommend starting HCV treatment in
HIV/HCV-coinfected patients in whom HIV is stably
Figure 2. Pharmacokinetic effects of faldaprevir coadministered with darunavir/ritonavir, efavirenz, tenofovir, and midazolam. A, Adjusted GMR (90% CI)
of faldaprevir AUC, Cmax, and Cmin (see Abbreviations for deﬁnitions) with/without coadministered drug (adjusted for effects in analysis of variance model).
B, Adjusted GMR (90% CI) of coadministered drug AUC, Cmax, and Cmin with/without administration of faldaprevir. Abbreviations: AUC, area under the
concentration–time curve; CI, conﬁdence interval; Cmax, maximum plasma concentration; Cmin, minimum plasma concentration; GMR, geometric mean ratio;
PK, pharmacokinetic.
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controlled with cART [11]. Therefore, effective HCV direct-
acting antiviral agents that have a low potential for drug–drug
interactions with ARVs could be highly beneﬁcial for the treat-
ment of HIV/HCV-coinfected individuals. In the 3 phase 1
studies in healthy volunteers described here, potential
drug–drug interactions between faldaprevir and commonly
used ARVs were examined in an effort to provide dosing
recommendations for patients receiving faldaprevir in combi-
nation with peg-IFN and RBV plus darunavir/ritonavir, efavir-
enz, or tenofovir in the pivotal phase 3 trial in coinfected
patients (STARTVerso4). In all studies, faldaprevir coadminis-
tered with ARVs was well tolerated and AEs were predominant-
ly mild in intensity.
Coadministration of faldaprevir 240 mg twice daily with efa-
virenz in healthy volunteers resulted in an approximate 35% re-
duction in faldaprevir AUC and 46% reduction in faldaprevir
Cmin due to CYP3A induction by efavirenz. Despite induction
of CYP3A by efavirenz, coadministration of efavirenz had no
impact on the metabolite proﬁle of faldaprevir in plasma
(data not shown). The predominant metabolites of faldaprevir
are M2a and M2b; their formation via CYP3A4/5 and clearance
from the circulation have been described in a recent publication
[19]. Both metabolites have a low permeability, and thus are not
expected to diffuse readily into the blood or be absorbed effec-
tively by the gastrointestinal tract. Rapid uptake into the liver by
hepatic uptake transporters was also noted. In the presence of
efavirenz, where faldaprevir clearance is increased, the low levels
of metabolites permeating into the blood, combined with the ef-
ﬁcient clearance into bile from the liver, is likely to be the reason
that the levels of these metabolites in plasma remained un-
changed. Clinical doses of faldaprevir that have been investigated
in HCV genotype 1–infected patients are 120 and 240 mg once
daily. In STARTVerso4, faldaprevir was utilized at the 240 mg
once-daily dose when coadministered with efavirenz based on
the decrease in faldaprevir exposure presented here. Preliminary
data from STARTVerso4 suggest that this combination is effec-
tive and the safety proﬁle is similar to that observed in HCV ge-
notype 1–monoinfected patients [4]. Faldaprevir 240 mg once
daily would therefore be the appropriate dose when coadminis-
tered with efavirenz in HIV/HCV-coinfected patients.
Faldaprevir 240 mg once daily had no clinically relevant
effect on darunavir exposure when coadministered with daru-
navir/ritonavir (15% increase in darunavir AUC). Ritonavir is
a moderate-to-strong in vivo inhibitor of CYP3A, depending
on dose and regimen [16]. Darunavir is mainly metabolized
by CYP3A and ritonavir is used to boost darunavir exposure
by inhibition of CYP3A [20]. Faldaprevir is a substrate of
CYP3A; thus, ritonavir is likely to also increase faldaprevir ex-
posure. Preliminary data from STARTVerso4 suggest that fal-
daprevir 120 mg once daily coadministered with darunavir/
ritonavir is effective and the safety proﬁle is similar to that ob-
served in HCV genotype 1–monoinfected patients [4]. Togeth-
er, these results suggest that faldaprevir 120 mg once daily
would be an appropriate dose to use in combination with dar-
unavir/ritonavir.
The observed small, 2-sided interaction between faldaprevir
and tenofovir was not considered to be clinically relevant
(22% decrease in faldaprevir AUC; 22% increase in tenofovir
Table 4. Adverse Events, Irrespective of Causality, Occurring in
>1 Patient
Adverse Event
Darunavir/
Ritonavir
Study (n = 14)
Efavirenz
Study
(n = 15)
Tenofovir
Study
(n = 16)
Any adverse event 11 (78.6) 15 (100) 16 (100)
Any moderate adverse
event
4 (28.6) 11 (73.3) 3 (18.8)
Any severe adverse event 0 0 0
Gastrointestinal disorders
Diarrhea 6 (42.9) 4 (26.7) 8 (50.0)
Abdominal distension 4 (28.6) 0 0
Nausea 2 (14.3) 8 (53.3) 6 (37.5)
Flatulence 1 (7.1) 0 0
Vomiting 1 (7.1) 2 (13.3) 5 (31.5)
Abdominal pain 0 2 (13.3) 0
Upper abdominal pain 0 0 2 (12.5)
Dry mouth 0 2 (13.3) 0
Nervous system disorders
Headache 4 (28.6) 5 (33.3) 10 (62.5)
Dizziness 1 (7.1) 12 (80.0) 1 (6.3)
Disturbance in attention 0 2 (13.3) 0
Psychiatric disorders
Sleep disorder 1 (7.1) 3 (20.0) 0
Abnormal dreams 0 4 (26.7) 0
General disorders and administration site conditions
Fatigue 3 (21.4) 5 (33.3) 0
Malaise 0 0 3 (18.8)
Feeling hot 0 3 (20.0) 0
Metabolism and nutrition disorders
Decreased appetite 1 (7.1) 0 2 (12.5)
Eye disorders
Ocular icterus 0 6 (40.0) 5 (31.3)
Hepatobiliary disorders
Jaundice 0 6 (40.0) 5 (31.3)
Musculoskeletal and connective tissue disorders
Myalgia 0 0 7 (43.8)
Arthralgia 0 0 2 (12.5)
Skin and subcutaneous tissue disorders
Rash 0 7 (46.7) 1 (6.3)
Hyperhidrosis 0 2 (13.3) 0
Injury, poisoning, and procedural complications
Sunburn/thermal burn 0 2 (13.1) 0
Data are presented as No. (%).
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AUC), and the values are in line with the increases in PK pa-
rameters seen when tenofovir is coadministered with lopinavir
and ritonavir (AUC, 32% increase; Cmax, no change; Cmin, 51%
increase), and darunavir and ritonavir (AUC, 22% increase;
Cmin, increase 37%) where no dose adjustment is indicated
[17]. Therefore, we do not consider faldaprevir dose adjustment
to be necessary when coadministered with tenofovir. In
STARTVerso4, tenofovir was used as part of the backbone ther-
apy in patients treated with a lower dose of faldaprevir (120 mg
once daily and 240 mg once daily) without any particular safety
concerns and, therefore, either faldaprevir 120 or 240 mg once
daily would be considered appropriate doses to use in combina-
tion with tenofovir [4]. In patients with renal impairment, close
monitoring of kidney function and dose reduction of tenofovir
is recommended [17], so the potential increase in tenofovir-re-
lated events with the increased exposure would be reduced
when coadministered with faldaprevir.
The type and magnitude of drug–drug interaction varies
depending on which HCV protease inhibitor is coadministered
with ARVs. The NS3/4A HCV protease inhibitors boceprevir
and telaprevir are strong CYP3A inhibitors and CYP3A sub-
strates, and clinically relevant drug–drug interactions with
ARVs and contraindications for coadministration with speciﬁc
ARVs are well documented [21–23]. Coadministration of boce-
previr and efavirenz is not recommended, whereas dose adjust-
ments are required when efavirenz is coadministered with
telaprevir [21–24]. Neither boceprevir nor telaprevir is recom-
mended to be administered in combination with darunavir/rito-
navir because of decreases in exposure of boceprevir (32%) and
telaprevir (35%), and concomitant decreases in darunavir expo-
sure (44% and 40%, respectively) [22–25]. The mechanisms for
such unusual drug–drug interactions have not been clearly deter-
mined, but these effects cannot be explained by predictable
mechanisms of CYP3A inhibition [26]. The HCV NS3/4A pro-
tease inhibitor simeprevir is a sensitive substrate of CYP3A and a
mild inhibitor of intestinal CYP3A. Coadministration of simepre-
vir with efavirenz or ritonavir-boosted protease inhibitors such as
darunavir/ritonavir is not recommended due to a signiﬁcant de-
crease in simeprevir exposure with efavirenz and a signiﬁcant in-
crease in exposure with ritonavir [27, 28].
In summary, results of these phase 1 studies demonstrate
that faldaprevir drug interactions with ARVs appear to be pre-
dictable based on the metabolism of faldaprevir by CYP3A and
inhibition of CYP3A by faldaprevir and that any changes in fal-
daprevir exposure could be managed using either 120 mg once
daily or 240 mg once daily.
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